Acarbose
Aliases: Acarbose · Glucobay
Last verified: 2026-09-23
The short version
An alpha-glucosidase inhibitor — slows carbohydrate absorption; ITP program: lifespan extension in male mice (+22%); geroprotector candidate.
Identity & type
- Molecular type
- mali molekul
- Origin
- An alpha-glucosidase inhibitor — slows carbohydrate absorption; ITP program: lifespan extension in male mice (+22%); geroprotector candidate.
Mechanism of action
Blocks intestinal α-glucosidase → smaller glucose spikes; secondary metabolic effects.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 25–100 mg with meals 3×/day.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
25–100 mg with meals 3×/day. In diabetics: steadier post-meal glucose; the longevity community rarely uses it due to gas/bloating.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
In diabetics: steadier post-meal glucose; the longevity community rarely uses it due to gas/bloating.
Protocol — official vs community
Official / label
Approved for T2D (25–100 mg TID with first bite of each meal). ITP mouse lifespan data drives longevity interest.
- 01Start 25 mg TID, titrate to 50–100 mg TID by postprandial glucose
Duration: Continuous.
Alpha-glucosidase inhibitor — flattens the glucose spike at the cost of flatulence (the price of mechanism).
Community (anecdotal)
25–50 mg with the largest-carb meals only (selective use) or TID per label.
- Cycle:
- Continuous.
- Break:
- None.
The ITP (Interventions Testing Program) lifespan signal is the strongest animal-rationale in the codex for a prescription drug.
Human evidence
ITP longevity data; standard antidiabetic in Asia.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Bloating, gas (common).characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials